Ignacio Melero
#127,307
Most Influential Person Now
Ignacio Melero's AcademicInfluence.com Rankings
Ignacio Meleromedical Degrees
Medical
#2051
World Rank
#2445
Historical Rank
Oncology
#112
World Rank
#116
Historical Rank
Ignacio Melerobiology Degrees
Biology
#8145
World Rank
#11179
Historical Rank
Immunology
#458
World Rank
#475
Historical Rank
Download Badge
Medical Biology
Ignacio Melero's Degrees
- Bachelors Biology Complutense University of Madrid
- Masters Biotechnology Complutense University of Madrid
- PhD Immunology University of Barcelona
Similar Degrees You Can Earn
Why Is Ignacio Melero Influential?
(Suggest an Edit or Addition)Ignacio Melero's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial (2017) (2764)
- Dendritic cells in cancer immunology and immunotherapy (2019) (945)
- Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors (1997) (944)
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. (2013) (798)
- Therapeutic vaccines for cancer: an overview of clinical trials (2014) (610)
- Immunostimulatory monoclonal antibodies for cancer therapy (2007) (597)
- Evolving synergistic combinations of targeted immunotherapies to combat cancer (2015) (526)
- Cytokines in clinical cancer immunotherapy (2018) (496)
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3 (2019) (445)
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib (2020) (433)
- Direct Effects of Type I Interferons on Cells of the Immune System (2011) (427)
- Immunological landscape and immunotherapy of hepatocellular carcinoma (2015) (425)
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. (2017) (397)
- Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma (2019) (381)
- NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. (1998) (371)
- Classification of current anticancer immunotherapies (2014) (357)
- Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes (2019) (330)
- Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. (2004) (307)
- Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. (2016) (306)
- Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. (2010) (282)
- Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. (2018) (278)
- Advances in immunotherapy for hepatocellular carcinoma (2021) (277)
- T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. (2014) (276)
- Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients (2017) (274)
- CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. (2020) (262)
- Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs) (2016) (252)
- Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. (2018) (247)
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody (2016) (243)
- Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy (2019) (239)
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. (2021) (230)
- Interleukin-8 in cancer pathogenesis, treatment and follow-up. (2017) (223)
- Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. (2015) (219)
- Emerging Opportunities and Challenges in Cancer Immunotherapy (2016) (209)
- CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination 1 (2003) (207)
- Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors (2020) (202)
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. (2019) (187)
- Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells (2017) (186)
- Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes (2009) (185)
- Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. (2005) (185)
- Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins (2014) (180)
- Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. (2015) (176)
- Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. (2017) (175)
- Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination (2013) (174)
- Molecular Pathways: Hypoxia Response in Immune Cells Fighting or Promoting Cancer (2011) (173)
- The CD94/NKG2-A inhibitory receptor complex is involved in natural killer cell-mediated recognition of cells expressing HLA-G1. (1997) (170)
- Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes (2017) (169)
- Intratumoral Coinjection of Two Adenoviruses, One Encoding the Chemokine IFN-γ-Inducible Protein-10 and Another Encoding IL-12, Results in Marked Antitumoral Synergy1 (2000) (169)
- PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma (2015) (168)
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma (2020) (167)
- Predictors of responses to immune checkpoint blockade in advanced melanoma (2017) (162)
- Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint (2020) (156)
- Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. (2016) (156)
- Immunological impact of cell death signaling driven by radiation on the tumor microenvironment (2019) (152)
- Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses (2003) (152)
- Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells (2013) (152)
- Defining the critical hurdles in cancer immunotherapy (2011) (152)
- Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally (2017) (151)
- Radiation effects on antitumor immune responses: current perspectives and challenges (2018) (150)
- Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. (2006) (149)
- Targeting NK-cell checkpoints for cancer immunotherapy. (2017) (145)
- Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis (2019) (144)
- The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. (2012) (142)
- Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells (2017) (139)
- Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. (2006) (137)
- Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy (2017) (136)
- Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas (1999) (136)
- Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. (2016) (135)
- An RNA toolbox for cancer immunotherapy (2018) (133)
- Functional ambivalence of the Kp43 (CD94) NK cell-associated surface antigen. (1995) (133)
- IL‐10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis (2008) (126)
- Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice. (2015) (124)
- Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? (2016) (124)
- Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). (2017) (119)
- Consensus nomenclature for CD8+ T cell phenotypes in cancer (2015) (118)
- Orchestrating immune check-point blockade for cancer immunotherapy in combinations. (2014) (118)
- Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. (2011) (117)
- Dendritic cells delivered inside human carcinomas are sequestered by interleukin‐8 (2005) (116)
- Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) (2018) (114)
- Immune response regulation in the tumor microenvironment by hypoxia. (2015) (109)
- Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. (2008) (109)
- Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. (2001) (109)
- Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ (2010) (108)
- Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. (2007) (104)
- Intratumoural administration and tumour tissue targeting of cancer immunotherapies (2021) (104)
- The clinical application of cancer immunotherapy based on naturally circulating dendritic cells (2019) (103)
- LBA18Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations (2017) (103)
- Innate immune mediators in cancer: between defense and resistance (2016) (101)
- PD-L1 expression as a potential predictive biomarker. (2015) (97)
- Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12 (2001) (97)
- Deciphering CD137 (4‐1BB) signaling in T‐cell costimulation for translation into successful cancer immunotherapy (2016) (96)
- Paradigms on Immunotherapy Combinations with Chemotherapy. (2021) (95)
- Immunization with a tumor‐associated CTL epitope plus a tumor‐related or unrelated Th1 helper peptide elicits protective CTL immunity (2001) (94)
- Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model (2013) (94)
- IL-12 gene therapy for cancer: in synergy with other immunotherapies. (2001) (92)
- Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb (2015) (89)
- Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients (2017) (88)
- Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16 (1997) (86)
- A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity (2018) (86)
- Gene therapy of cancer based on interleukin 12. (2005) (86)
- Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array (2009) (85)
- The NKB1 and HP-3E4 NK cells receptors are structurally distinct glycoproteins and independently recognize polymorphic HLA-B and HLA-C molecules. (1995) (83)
- Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. (2019) (83)
- B7-H3 Promotes Pathogenesis of Autoimmune Disease and Inflammation by Regulating the Activity of Different T Cell Subsets (2015) (81)
- Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma (2008) (80)
- T Cell Migration from Inflamed Skin to Draining Lymph Nodes Requires Intralymphatic Crawling Supported by ICAM-1/LFA-1 Interactions. (2017) (80)
- Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. (2020) (78)
- Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade (2015) (77)
- CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. (2021) (76)
- Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. (2017) (76)
- CD4 /CD25 Regulatory Cells Inhibit Activation of Tumor-Primed CD4 T Cells with IFN- -Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination (2003) (75)
- Bone-marrow-derived cell differentiation into microglia: A study in a progressive mouse model of Parkinson's disease (2007) (74)
- Strategies to design clinical studies to identify predictive biomarkers in cancer research. (2017) (74)
- Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen (2019) (73)
- Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens (2004) (71)
- Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials (2016) (67)
- Immunotherapeutic effects of intratumoral nanoplexed poly I:C (2019) (66)
- Gene therapy of cancer with interleukin-12. (2003) (66)
- Tyrosine kinase-dependent activation of human NK cell functions upon stimulation through a 58-kDa surface antigen selectively expressed on discrete subsets of NK cells and T lymphocytes. (1994) (65)
- Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level. (2000) (64)
- SimB16: Modeling Induced Immune System Response against B16-Melanoma (2011) (63)
- Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. (2019) (62)
- Effects of IFN‐α as a signal‐3 cytokine on human naïve and antigen‐experienced CD8+ T cells (2010) (62)
- CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs (2018) (62)
- Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN‐α (2010) (62)
- Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer (2019) (62)
- Biochemical and serologic evidence for the existence of functionally distinct forms of the CD94 NK cell receptor. (1996) (62)
- Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients (2011) (60)
- New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis (2020) (59)
- Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates (2012) (58)
- In vivo depletion of DC impairs the anti‐tumor effect of agonistic anti‐CD137 mAb (2009) (58)
- T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63–Polyubiquitin-Dependent Signals from Endosomes (2013) (58)
- Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus (2021) (58)
- A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy. (2021) (57)
- Revisiting Interleukin-12 as a Cancer Immunotherapy Agent (2018) (55)
- Immunotherapy for neurological diseases. (2008) (55)
- Feeding dendritic cells with tumor antigens: self-service buffet or à la carte? (2000) (54)
- Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. (2012) (53)
- Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. (1997) (52)
- Signaling through the LFA‐1 leucocyte integrin actively regulates intercellular adhesion and tumor necrosis factor‐α production in natural killer cells (1993) (52)
- IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy (2020) (52)
- Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation (2018) (52)
- TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies (2019) (51)
- Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12 (2001) (50)
- A Network Analysis of the Human T-Cell Activation Gene Network Identifies Jagged1 as a Therapeutic Target for Autoimmune Diseases (2007) (49)
- Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium. (2017) (47)
- CD137 on inflamed lymphatic endothelial cells enhances CCL21‐guided migration of dendritic cells (2012) (47)
- Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming. (2018) (47)
- Lymphatic endothelium forms integrin-engaging 3D structures during DC transit across inflamed lymphatic vessels. (2013) (47)
- Lysine 63 Polyubiquitination in Immunotherapy and in Cancer-promoting Inflammation (2009) (46)
- Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040. (2018) (45)
- Cellular cytotoxicity is a form of immunogenic cell death (2020) (44)
- Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. (2005) (44)
- Immunotherapy and immunoescape in colorectal cancer. (2007) (44)
- Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming. (2002) (43)
- Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication. (2006) (43)
- Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach. (2008) (42)
- Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 (2013) (42)
- Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity (2018) (42)
- Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism (2014) (41)
- Metabolic Consequences of T-cell Costimulation in Anticancer Immunity (2019) (41)
- Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study. (2016) (40)
- Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies (2002) (40)
- Intratumoral injection of interferon‐α and systemic delivery of agonist anti‐CD137 monoclonal antibodies synergize for immunotherapy (2011) (40)
- Cancer vaccines: the next immunotherapy frontier (2022) (38)
- Carcinoma-Derived Interleukin-8 Disorients Dendritic Cell Migration Without Impairing T-Cell Stimulation (2011) (38)
- Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy. (2016) (38)
- Immune mechanisms mediating abscopal effects in radioimmunotherapy (2019) (38)
- Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. (2013) (38)
- Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. (2003) (38)
- Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNγ-induced apoptosis (2003) (37)
- Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti–PD‐1 and Anti‐CD137 Monoclonal Antibodies (2016) (37)
- The promise of gene therapy in gastrointestinal and liver diseases (2003) (37)
- Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells (2010) (37)
- CD8 T Cell Priming in the Presence of IFN-α Renders CTLs with Improved Responsiveness to Homeostatic Cytokines and Recall Antigens: Important Traits for Adoptive T Cell Therapy (2012) (36)
- Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study. (2016) (35)
- T-Cell and NK-Cell Infi ltration into Solid Tumors: A Key Limiting Factor for Effi cacious Cancer Immunotherapy (2014) (35)
- Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12. (2015) (35)
- Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors (2020) (34)
- Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates. (2010) (34)
- Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. (2017) (34)
- Interleukin-15 in gene therapy of cancer. (2012) (34)
- Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb (2013) (33)
- Prognostic value of macrophage polarization markers in epithelial neoplasms and melanoma. A systematic review and meta-analysis (2020) (32)
- Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12. (2002) (31)
- Dendritic Cells Take up and Present Antigens from Viable and Apoptotic Polymorphonuclear Leukocytes (2011) (31)
- Initial Afferent Lymphatic Vessels Controlling Outbound Leukocyte Traffic from Skin to Lymph Nodes (2013) (30)
- Cellular immunotherapies for cancer (2017) (30)
- Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy (2015) (29)
- Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells (2008) (28)
- Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy (2017) (28)
- CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes (2017) (28)
- Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040. (2021) (28)
- Palettes of Vaccines and Immunostimulatory Monoclonal Antibodies for Combination (2009) (28)
- Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer (2007) (28)
- Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study. (2017) (28)
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma (2021) (27)
- Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL‐8 (2021) (27)
- Intratumoral injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells. (2005) (27)
- OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors (2020) (26)
- Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria. (2010) (26)
- An anti-ICAM-2 (CD102) monoclonal antibody induces immune-mediated regressions of transplanted ICAM-2-negative colon carcinomas. (2002) (25)
- Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer (2019) (25)
- αvβ3 Integrin-Mediated Adenoviral Transfer of Interleukin-12 at the Periphery of Hepatic Colon Cancer Metastases Induces VCAM-1 Expression and T-Cell Recruitment (2001) (25)
- Immunogenic Cell Death and Cross-Priming Are Reaching the Clinical Immunotherapy Arena (2006) (25)
- Diverse immune environments in human lung tuberculosis granulomas assessed by quantitative multiplexed immunofluorescence (2020) (25)
- An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors (2019) (25)
- Repurposing the yellow fever vaccine for intratumoral immunotherapy (2019) (24)
- Expression and function of alpha 4/beta 7 integrin on human natural killer cells. (1996) (24)
- A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis (2018) (23)
- Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies. (2017) (23)
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040. (2020) (23)
- Cytokine gene transfer into dendritic cells for cancer treatment. (2002) (23)
- Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer. (2020) (22)
- LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study) (2020) (22)
- LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study (2021) (22)
- Stimulation of IL-2-activated natural killer cells through the Kp43 surface antigen up-regulates TNF-alpha production involving the LFA-1 integrin. (1993) (22)
- Cell tracking using multimodal imaging. (2013) (22)
- Twists and turns to translating 4-1BB cancer immunotherapy (2019) (22)
- The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNγ (2007) (21)
- Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death (2020) (21)
- Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15 (2018) (21)
- Genetic basis for clinical response to CTLA-4 blockade. (2015) (21)
- Changing the tumor microenvironment: new strategies for immunotherapy. (2012) (21)
- CD69 is a direct HIF-1α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes (2017) (20)
- Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses. (2019) (20)
- Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial (2022) (19)
- Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”, Napoli, December 5th-8th 2013 (2014) (19)
- Functional expression of CD137 (4-1BB) on T helper follicular cells (2015) (19)
- Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis. (2013) (19)
- Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by β-Catenin Activation. (2019) (19)
- Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? (2009) (19)
- Functional analysis of α1β1 integrin in human natural killer cells (1996) (19)
- Effective tumor immunotherapy: start the engine, release the brakes, step on the gas pedal,...and get ready to face autoimmunity. (2002) (18)
- Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells (2019) (18)
- Synergistic effects of CTLA‐4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo (2011) (18)
- PET imaging of thymidine kinase gene expression in the liver of non-human primates following systemic delivery of an adenoviral vector (2009) (17)
- Repurposing infectious disease vaccines for intratumoral immunotherapy (2020) (17)
- ICAM-1-LFA-1 Dependent CD8+ T-Lymphocyte Aggregation in Tumor Tissue Prevents Recirculation to Draining Lymph Nodes (2018) (17)
- Alpha(v)beta(3) integrin-mediated adenoviral transfer of interleukin-12 at the periphery of hepatic colon cancer metastases induces VCAM-1 expression and T-cell recruitment. (2001) (16)
- Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage? (2016) (16)
- Immunodivergence in Metastatic Colorectal Cancer. (2018) (16)
- Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors (2020) (16)
- Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v). (2018) (15)
- Differential Interleukin‐8 thresholds for chemotaxis and netosis in human neutrophils (2020) (15)
- Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity (2019) (15)
- Liver Gene Transfer of Interkeukin-15 Constructs That Become Part of Circulating High Density Lipoproteins for Immunotherapy (2012) (15)
- 403PPhase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC) (2017) (15)
- Immunological Ignorance of an E 7-Encoded Cytolytic T-Lymphocyte Epitope in Transgenic Mice Expressing the E 7 and E 6 Oncogenes of Human Papillomavirus Type 16 (1997) (14)
- A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL). (2013) (14)
- Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011 (2012) (14)
- Cancer Immunotherapy Principles and Practice (2018) (13)
- EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372). (2016) (13)
- Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC). (2017) (13)
- Abstract 4387: Antiviral and antitumoral effects of the anti-CTLA4 agent tremelimumab in patients with hepatocellular carcinoma (HCC) and chronic hepatitis C virus (HCV) infection: Results from a phase II clinical trial (2012) (13)
- Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy) (2018) (12)
- Treatment with monoclonal antibodies (mAbs) against the 4-1BB T-cell activation molecule eradicate established tumors (1997) (12)
- LBA-004Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC). (2017) (12)
- Intratumoural administration of dendritic cells: hostile environment and help by gene therapy (2005) (11)
- DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells (2021) (11)
- Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors (2022) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic (2021) (11)
- Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression (2015) (11)
- Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy (2021) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma (HCC): Survival, Hepatic Safety, and Biomarker Assessments in CheckMate 040 (2017) (10)
- 1025MO First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours (2020) (10)
- Biologic therapy of liver tumors. (2004) (9)
- An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity (2021) (9)
- Agonist Anti-CD 137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes (2011) (9)
- Tumor ENPP1(CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer. (2022) (9)
- Better Performance of CARs Deprived of the PD-1 Brake (2013) (9)
- Hepatic safety and biomarker assessments in sorafenib-experienced patients with advanced hepatocellular carcinoma treated with nivolumab in the CheckMate-040 study (2018) (9)
- Nivolumab in sorafenib-naive and - experienced patients with advanced hepatocellular carcinoma (HCC): checkMate 040 study (2017) (9)
- Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors (2020) (9)
- CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation. (2015) (9)
- Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco‐induced lung cancer (2018) (9)
- The many sounds of T lymphocyte silence (2005) (9)
- Innate Functions of Immunoglobulin M Lessen Liver Gene Transfer with Helper-Dependent Adenovirus (2014) (8)
- Anti-ICAM-2 monoclonal antibody synergizes with intratumor gene transfer of interleukin-12 inhibiting activation-induced T-cell death. (2003) (8)
- 1181PPharmacokinetics (PK) and Pharmacodynamics (PD) of cergutuzumab amunaleukin (CA), a carcinoembryonic antigen (CEA)-targeted interleukin 2 variant (IL2v) with abolished binding to CD25 (2017) (8)
- Virotherapy, gene transfer and immunostimulatory monoclonal antibodies (2012) (8)
- Revisiting Anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy. (2020) (8)
- Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study (2017) (8)
- Cancer immunotherapy full speed ahead. (2017) (8)
- Novel strategies exploiting interleukin-12 in cancer immunotherapy. (2022) (8)
- Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms (2020) (8)
- Absence of surface expression of CD137 (4-1BB) on Myeloid-derived suppressor cells (2007) (7)
- SimB 16 : Modeling Induced Immune System Response against B 16-Melanoma (2011) (7)
- The liver, liver metastasis and liver cancer: a special case for immunotherapy with cytokines and immunostimulatory monoclonal antibodies. (2012) (7)
- Antitumoral Synergy Encoding IL-12 , Results in Marked-Inducible Protein-10 and Another γ IFN-Adenoviruses , One Encoding the Chemokine Intratumoral Coinjection of Two Melero (2000) (7)
- Spatial transcriptomic characterization of COVID-19 pneumonitis identifies immune circuits related to tissue injury (2021) (7)
- Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory (2021) (6)
- Cancer Immunosurveillance Caught in the Act. (2016) (6)
- Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040 (2020) (6)
- Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors. (2018) (6)
- Advances in mRNA-based drug discovery in cancer immunotherapy (2021) (6)
- Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications (2021) (6)
- 286 Tumor targeting and tissue biodistribution of RO7122290, a novel FAP-targeted 4–1BB (CD137) agonist, in patients with advanced solid tumors, using [89Zr]-RO7122290 as a PET tracer (2020) (6)
- Thrombopenic purpura induced by a monoclonal antibody directed to a 35-kilodalton surface protein (p35) expressed on murine platelets and endothelial cells. (2001) (6)
- Cardiotrophin-1 determines liver engraftment of syngenic colon carcinoma cells through an immune system-mediated mechanism (2012) (6)
- Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack (2019) (5)
- Awareness and understanding of cancer immunotherapy in Europe (2014) (5)
- Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer (2014) (5)
- Functional analysis of alpha 1 beta 1 integrin in human natural killer cells. (1996) (5)
- Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors (2021) (5)
- B 7-H 3 Promotes Pathogenesis of Autoimmune Disease and Inflammation by Regulating the Activity of Different T Cell Subsets (2017) (5)
- Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better? (2018) (5)
- Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4–1BB) (2018) (5)
- Abstract 2675: Assessment of inflammation biomarkers in relation to clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040 (2019) (5)
- Immunotherapy of hepatocellular carcinoma. (2014) (4)
- Polly Matzinger's “danger model” finds its predicted danger-denoting self moieties (2008) (4)
- 755 CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity (2020) (4)
- [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases]. (2006) (4)
- Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop. (2016) (4)
- Abstract 4908: Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires Batf3-dependent dendritic cells (2016) (4)
- Functional resemblance between the Ig-related NK cell receptors specific for HLA class I molecules and the CD94 C-type lectin. (1996) (4)
- 1134. Intratumoral Injection of Dendritic Cells Engineered to Secrete Interleukin-12 by Recombinant Adenovirus in Patients with Metastatic Gastrointestinal Carcinomas (2005) (4)
- CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function (2021) (4)
- 394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results (2020) (4)
- Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors (2020) (4)
- For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity (2018) (4)
- Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants (2021) (4)
- High-density lipoproteins delivering interleukin-15 (2013) (4)
- FRI-499-Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040 (2019) (4)
- 412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors (2020) (4)
- A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER). (2021) (4)
- Consolidating Radiotherapy with Immunotherapy (2021) (3)
- First-in-human clinical trial with intratumoral BO-112 in solid malignancies: A novel immunotherapy based in double-stranded RNA (dsRNA). (2017) (3)
- Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers (2022) (3)
- Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy (2019) (3)
- Therapeutic activity of a combination of immunostimulatory monoclonal antibodies (anti-B7-H1, CD137 and OX40) on a c-myc-driven spontaneous transgenic model of hepatocellular carcinoma (2013) (3)
- Omentum: Friend or foe in ovarian cancer immunotherapy? (2022) (3)
- 219O Safety and preliminary efficacy of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the phase 1/2 CheckMate-040 study (2016) (3)
- Oncology Phase I Trial Design and Conduct: Time for a Change MDICT Guidelines 2022. (2022) (3)
- A therapeutically actionable pro-tumoral axis of cytokines involving interleukin-8, TNFa and IL-1B. (2022) (3)
- 91P Phase I dose escalation of IMC-C103C, a CD3×MAGE-A4 T-cell receptor (TCR) bispecific protein (2021) (3)
- Epistatic Oncogenic Interactions Determine Cancer Susceptibility to Immunotherapy. (2018) (3)
- Biomarkers and clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040 (2019) (3)
- LBA20Safety and immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in solid malignancies: First in human clinical trial (2017) (2)
- CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary. (2022) (2)
- Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer (2019) (2)
- Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies (2022) (2)
- Nivolumab (Nivo) in Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC): the CheckMate 040 Study (2016) (2)
- Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021 (2022) (2)
- Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control (2023) (2)
- Awareness and understanding of cancer immunotherapy in Europe. (2013) (2)
- 370 Pharmacodynamic assessment of a novel FAP-targeted 4–1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors (2020) (2)
- 104PPharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA-CD3 TCB) for the treatment of CEA-positive solid tumors (2017) (2)
- Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers (2022) (2)
- P1318 : Phase I dose escalation study of the safety, immunoregulatory activity, pharmacokinetics, and preliminary antitumor activity of nivolumab in advanced hepatocellular carcinoma in patients with or without chronic viral hepatitis (2015) (2)
- 15PDIn patients with advanced non-small cell lung cancer (NSCLC) LAG-3 is expressed on activated TILs and predicts resistance to PD-1 axis blockers (2017) (2)
- Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma (2021) (2)
- Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors. (2018) (2)
- MONEO: A phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC). (2021) (2)
- Identification through genome-wide association study (GWAS) of single nucleotide polymorphisms (SNPs) associated with extreme phenotypes of tobacco-induced non-small cell lung cancer (NSCLC) risk. (2014) (2)
- Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma (2021) (2)
- Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment. (2022) (2)
- Immunotherapy of Cancer Visualized by Live Microscopy: Seeing Is Believing (2016) (2)
- LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation (2022) (2)
- Introducing a New Series: Immunotherapy Facts and Hopes (2018) (2)
- Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study (2016) (2)
- Rapid isolation and enrichment of mouse NK cells for experimental purposes. (2020) (2)
- MAGE antigens: therapeutic targets in hepatocellular carcinoma? (2004) (2)
- Efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma analyzed by patient age: A sub-analysis of the CheckMate 040 study. (2017) (2)
- SO-12 Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040 (2022) (2)
- [Active immunotherapy in the treatment of haematological neoplasias]. (2004) (2)
- Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis (2022) (1)
- Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8+ T cells eradicates peritoneal metastases in mouse models (2022) (1)
- Abstract 3538: The HIF-1α hypoxia response in mouse tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy (2012) (1)
- Cover Picture: IL‐10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis – Eur. J. Immunol. 2/2008 (2008) (1)
- Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma (2021) (1)
- Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2IL2R (2015) (1)
- Abstract 639: Morphological changes in mitochondria induced by CD137 (4-1BB) co-stimulation on CD8 T cells (2017) (1)
- Immunology and Gene Therapy: Shoulder to Shoulder Into the Fray (2010) (1)
- Activation-induced T-Cell Death Intratumor Gene Transfer of Interleukin-12 Inhibiting Anti-ICAM-2 Monoclonal Antibody Synergizes with (2003) (1)
- Premortem Tumor Stress in Radioimmunotherapy. (2020) (1)
- The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients (2022) (1)
- [Role of interleukin-12 in cancer immunotherapy]. (2004) (1)
- Intratumoral gene transfer of mRNAs encoding interleukin-12 in combination with decoy-resistant interleukin-18 improves local and systemic antitumor immunity. (2022) (1)
- Harmful cytokines in cancer immunology and immunotherapy: biomarkers and targets? (2021) (1)
- Overcoming the limitations of cytokines to improve cancer therapy. (2022) (1)
- 547 CERPASS: A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (2021) (1)
- 42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC) (2021) (1)
- Proliferating NK cells in response to IL-15 do not upregulate surface B220 in vivo (2010) (1)
- Routing cancer immunology and immunotherapy from the lab to the clinic 4–5 th March 2014, Center for Applied Medical Research and University Clinic, Pamplona, Spain (2014) (1)
- Exploiting TCR Recognition of Shared Hotspot Oncogene-encoded Neoantigens (2020) (1)
- 200MO Anti–IL-8 BMS-986253 + nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with advanced cancer: Update of initial phase I results (2022) (1)
- Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA CD3 TCB) for the treatment of CEA-expressing solid tumors. (2017) (1)
- Abstract CT017: Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients (2018) (1)
- Interferon producing killer dendritic cells (IKDC): A matter of controversy (2010) (1)
- Gene therapy of primary and metastatic liver tumors. (2001) (1)
- Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates (2012) (1)
- Depletion of conventional type-1 dendritic cells in established tumors suppresses immunotherapy efficacy. (2022) (1)
- Interleukin-12 Message in a Bottle (2020) (1)
- Molecular and cellular basis for immunomodulation with monoclonal antibodies (2015) (1)
- Clinical Bene fi t Associated With Idiotypic Vaccination in Patients With Follicular Lymphoma (2006) (1)
- Heterogenous presence of Neutrophil Extracellular Traps in human solid tumours is partially dependent on Interleukinâ•’8 (2021) (1)
- Changes in serum IL8 levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients (2016) (1)
- A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity (2018) (1)
- Antibody therapy (WS-101) Chairpersons: Norihiro Nishimoto, Yoshiya Tanaka (2010) (1)
- PS2-082 Immunological effects of gene transfer with the sushi domain of IL-15Rα and a chimeric protein consisting of IL-15 fused to apolipoprotein A-1 (2011) (1)
- PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab. (2020) (1)
- 745P Clinical activity, safety, and PK/PD from the first in human study (NP41300) of RO7247669, a PD1-LAG3 bispecific antibody (2022) (1)
- Co-stimulation Agonists via CD137, OX40, GITR, and CD27 for Immunotherapy of Cancer (2018) (1)
- 729MO Final results of the first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in combination with nivolumab in subjects with solid tumors relapsed/refractory to prior anti-PD1/PD-L1 treatment (2022) (1)
- Correction: Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells (2013) (1)
- Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021 (2022) (1)
- The many faces of regulatory T cells (2007) (1)
- DSTYK inhibition increases the sensitivity of lung cancer cells to T cell–mediated cytotoxicity (2022) (1)
- 173P First-in-human study to evaluate the safety and clinical activity of FS222: A tetravalent bispecific antibody targeting PD-L1 and CD137, in patients with advanced solid tumors (2022) (0)
- Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011 (2012) (0)
- Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors (2020) (0)
- 4-1BB (CD137) in anticancer chimeras (2020) (0)
- Previous immunotherapy treatments may improve tumor responses with subsequent chemotherapy regimens. (2018) (0)
- 320. Antitumor Effect of Intrahepatic Interleukin-12 Expression from a Regulable Plasmid Vector in Murine Models of Primary and Metastatic Liver Cancer (2005) (0)
- [Past, present and future of anti-idiotype vaccination]. (2004) (0)
- 505 Clinical evidence of intra-tumoral immune activation and tumor targeting with RG, a CEA-targeted engineered IL-2 immunocytokine (2015) (0)
- 106 Interferon-Producing Killer Dendritic Cells and Natural Killer Cells Response to Interleukin-15 Liver Gene Transfer (2007) (0)
- 1576PGENOME WIDE ASSOCIATION STUDY (GWAS) FOR IDENTIFICATION OF SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) ASSOCIATED WITH INDIVIDUALS PRESENTING EXTREME PHENOTYPES OF TOBACCO INDUCED NON-SMALL CELL LUNG CANCER (NSCLC) RISK. (2014) (0)
- Immunological impact of cell death signaling driven by radiation on the tumor microenvironment (2019) (0)
- 175P Safety and preliminary efficacy of GEN1042 (DuoBody-CD40x4-1BB) combination therapy in patients with advanced solid tumors (2022) (0)
- The combined actins of NK and T lymphocytes are necessary to reject a transplantable mesenchymal tumor through mechanisms partly dependent on KG2D (2006) (0)
- Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2 (cid:1) / (cid:1) IL2R g null Immunode fi cient Mice (2015) (0)
- Immunotherapythe Tumor Microenvironment: New Strategies for (2012) (0)
- Characterization through whole exome sequencing of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced non-small lung cancer (NSCLC). (2018) (0)
- Abstract LB-151: Prophylactic TNFα blockade unplugs toxicity and efficacy in immunotherapy anti-PD-1 + anti-CTLA-4 combinations (2018) (0)
- Immunology and Gene Therapy: Shoulder to Shoulder Into the Fray: International Symposium: Critical Frontiers Between Immunity and Gene Therapy Pamplona, Spain, 27-28 October 2009. (2010) (0)
- 157P Phase I expansion of IMC-C103C, a MAGE-A4×CD3 ImmTAC bispecific protein, in ovarian carcinoma (2022) (0)
- Dendritic cells in cancer immunology and immunotherapy (2019) (0)
- 270. Treatment of CT26 Tumors with Dendritic Cells Transduced with a Recombinant SV40 Vector Expressing Interleukine 15 (2004) (0)
- Critical appraisal of the current status of dendritic cell based therapy (2005) (0)
- EPS NSCLC SNPs Poster ESMO (2014) (0)
- 315 W0180 novel anti-VISTA antibody: Rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody (2020) (0)
- CTL differentiation and function (PP-108) (2010) (0)
- Abstract 6216: Intratumoral B0112 in combination with radiotherapy synergizes to achieve CD8 T cell mediated local tumor control (2022) (0)
- Abstract 3826: A therapeutically actionable pro-tumoral axis of cytokines involving interleukin-8, TNFα and IL-1β (2022) (0)
- Malignancies with Monoclonal Antibodies Potentiation of Therapeutic Immune Responses against Updated (2003) (0)
- Abstract 1223: Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. (2013) (0)
- Adoptive T Cell Therapy and Recall Antigens: Important Traits for Responsiveness to Homeostatic Cytokines Renders CTLs with Improved a CD8 T Cell Priming in the Presence of IFN-Ignacio (2012) (0)
- Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity (2022) (0)
- Abstract 4567: Polyubiquitin K63-related CD137 signalsomes in T cells stimulated with agonist anti-CD137 monoclonal antibodies (2011) (0)
- New trends in immunotherapy (2011) (0)
- Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma (2023) (0)
- Abstract 2331: Intratumor adoptive transfer of IL-12 mRNA transiently engineered anti-tumor CD8+ T cells (2019) (0)
- Cytokines in clinical cancer immunotherapy (2018) (0)
- 165TiP A first-in-human phase I study of FS222, a CD137/PD-L1 tetravalent bispecific antibody, in patients with advanced malignancies (2021) (0)
- PS1-010. CD8 T cell priming in the presence of IFNα improves memory differentiation and the efficacy of adoptive immunotherapy (2011) (0)
- Abstract 4012: Improving radiotherapy abscopal effects with anti-PD1 and anti-CD137-based immunotherapy (2016) (0)
- Liver Gene Therapy Approaches for Acute Intermittent Porphyria: Metabolic Correction and Immunological Hurdles (2013) (0)
- P-164 MONEO: A phase II study of avelumab plus FLOT in the peri-operative treatment for patients with resectable gastric or gastroesophageal junction cancer (2021) (0)
- Phase II study with immunotherapy with dendritic cells (DC) and intratumoral hiltonol in patients with advanced solid tumors. (2014) (0)
- Tu1483 - Hepatic Safety and Biomarker Assessments in Sorafenibexperienced Patients with Advanced Hepatocellular Carcinoma Treated with Nivolumab in the Checkmate-040 Study (2018) (0)
- Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 (2015) (0)
- Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015 (2016) (0)
- Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma (2019) (0)
- Enhancing T Cell Performance Against Cancer in Combination Treatment Strategies (2015) (0)
- 780TiP A phase I dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB Antibody) alone and in combination with pembrolizumab in patients with advanced malignancies (2022) (0)
- Antitumoral effects of intratumoral injection of two adenoviruses, one encoding IL-12 and another encodig MIP-3A in a murine model of liver metastatic pancreatic cancer (2002) (0)
- Abstract IA11: The immunotherapy faces of Interleukin-8 and CD137 (2019) (0)
- Melanoma Bridge 2013: Poster and Oral Presentations (2014) (0)
- 117PExternal validation of the Gustave Roussy immune score (GRIm score) in an unselected cohort of patients treated at the Clinica Universidad de Navarra (2018) (0)
- Abstract 1474: Repurposing the yellow fever vaccine for intratumoral immunotherapy (2019) (0)
- Revisiting intracavitary immunotherapy of cancer. (2022) (0)
- Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy (2023) (0)
- Polyubiquitin-Dependent Signals from - Monoclonal Antibodies Is Mediated by K63 T Cell Costimulation with Anti-CD137 (2013) (0)
- Indoleamine 2,3-dioxygenase: From tolerance during pregnancy to cancer (2005) (0)
- Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013 (2014) (0)
- 252PSERUM INTERLEUKIN-8 REFLECTS TUMOR BURDEN AND TREATMENT RESPONSE ACROSS MALIGNANCIES OF MULTIPLE TISSUE ORIGINS. (2014) (0)
- 1076TiPRANDOMIZED PHASE II TRIAL WITH DENDRITIC CELL (DC) IMMUNOTHERAPY IN PATIENTS WITH COLORECTAL CARCINOMA AND LIVER METASTASIS FOLLOWING COMPLETE RESECTION AND ADJUVANT CHEMOTHERAPY. (2014) (0)
- mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy (2022) (0)
- Abstract CT119: A randomized, double-blind phase 2 evaluation of the anti-IL-8 monoclonal antibody BMS-986253 + nivolumab + ipilimumab vs nivolumab + ipilimumab in patients with advanced melanoma that progressed on/after anti-PD-(L)1 therapy (2022) (0)
- Adenovirus mediated intratumoral gene transfer of IP-10 and IL-12 display potent antitumor synergy and improve adoptive T-cell therapy (2000) (0)
- 982 cDC1 cells are required to sustain CD8 T cell stemness in cancer and for the success at the onset of various immunotherapies. (2022) (0)
- Antitumor T-cell wars: do CD4s outwit CD8s? (2007) (0)
- 1134 AAV MEDIATED LIVER GENE THERAPY PROVIDES PROLONGED ENZYMATIC CORRECTION AND PROTECTS AGAINST INDUCED MOTOR NEUROPATHY IN ACUTE INTERMITTENT PORPHYRIA MICE (2010) (0)
- Abstract 281: Virotherapy with a Semliki Forest virus-based vector encoding IL-12 synergizes with PD-1/PD-L1 blockade (2015) (0)
- International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010 (2011) (0)
- 1078TiPPHASE II STUDY WITH IMMUNOTHERAPY WITH DENDRITIC CELLS (DC) COMBINED WITH INTRATUMORAL HILTONOL IN PATIENTS WITH ADVANCED CANCER. (2014) (0)
- Abstract 614: CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects (2023) (0)
- Designing clinical studies for biomarker discovery: The Design criteria (2020) (0)
- HT29 cells when xenografted secrete IL-8 to the plasma of the mice. (2011) (0)
- Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial (2021) (0)
- Randomized phase II study with dendritic cell (DC) immunotherapy in patients with resected hepatic metastasis of colorectal carcinoma. (2014) (0)
- MO24-1 Phase I/IIa trial evaluating safety and clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in advanced solid tumors (2021) (0)
- Firefighters for the Wrong Type of Inflammation in Tumors. (2021) (0)
- Expression of core and E1 proteins from hepatitis C virus in dendritic cells impairs T cell induction in vivo (2003) (0)
- Personalized Medicine and Imaging Serum Interleukin-8 Re fl ects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins (2014) (0)
- Abstract 1698: Cellular cytotoxicity is a form of immunogenic cell death (2020) (0)
- International Symposium: Trailblazing in Cancer Immunotherapy, October 29–31, 2017, Pamplona, Spain (2018) (0)
- Abstract B2: T cell costimulation in cancer immunotherapy with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes. (2013) (0)
- 516 Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody®-PD-L1×4–1BB (GEN1046) trial (2021) (0)
- Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer. (2022) (0)
- [New treatments for renal carcinoma]. (2007) (0)
- Abstract 4015: Exposure of lymphatic endothelial cells to ionizing radiation increases the surface expression levels of integrin ligands (2016) (0)
- Surfing the waves of the tide model of T cell co-stimulation (2012) (0)
- Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer (2022) (0)
- Routing cancer immunology and immunotherapy from the lab to the clinic 4–5 th March 2014, Center for Applied Medical Research and University Clinic, Pamplona, Spain (2014) (0)
- Therapeutic activity of a combination of immunostimulatory monoclonal antibodies (anti-B7-H1, CD137 and OX40) on a c-myc-driven spontaneous transgenic model of hepatocellular carcinoma (2013) (0)
- CD137/CD137 Ligand in Tumor and Viral Immunotherapy (2006) (0)
- Antibody therapy (PP-101) (2010) (0)
- Scavenger Receptor class B type I is Required for 25-Hydroxycholecalciferol Cellular Uptake and Signaling in Myeloid Cells. (2020) (0)
- 844 Combined immunotherapy efficacy on a multifocal hepatocellular carcinoma model based on hydrodynamic oncogene transfer (2022) (0)
- In vivo tracking of dendritic cells by SPECT/CT (2010) (0)
- Abstract 612: Methylation changes in DNA of CD8 T cells following CD137 costimulation (2017) (0)
- Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic (2023) (0)
- Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancer (2018) (0)
- REVISIONES Nuevos tratamientos para el carcinoma renal New treatments for renal carcinoma (2007) (0)
- [Specialized dendritic cells in cross-presentation of exogenous antigens to cytotoxic T lymphocytes]. (2013) (0)
- Serum interleukin-8 and its relationship to tumor burden and treatment response across malignancies of multiple tissue origins. (2014) (0)
- Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb (2014) (0)
- Abstract 2145: Genomic and transcriptomic analyses related to the clinical efficacy of first-line nivolumab in advanced hepatocellular carcinoma from the phase 3 CheckMate 459 trial (2022) (0)
- Predictors of responses to immune checkpoint blockade in advanced melanoma (2017) (0)
- 14P Comparison of the predictive power of survival of the Royal Marsden Score, the GRIM score and the LIPI score in phase I trial patients (2020) (0)
- Abstract 4740: Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment ofactivated T lymphocytes (2011) (0)
- 61INRATIONAL COMBINATIONS IN CANCER IMMUNOTHERAPY. (2014) (0)
- Identification of baseline predictive markers of sunitinib activity using a human cytokine antibody array in patients with metastatic renal cell carcinoma (MRCC). (2009) (0)
- OPTIMISING CANCER IMMUNOTHERAPY : CHALLENGES AND OPPORTUNITIES Summary of Presentations from a prIME Oncology Scientific Exchange on 21 st May 2016 in Amsterdam , Netherlands (2016) (0)
- Abstract 2887: Three dimensional colon cancer organoids model the response to CEA CD3 T cell engagers (2022) (0)
- 740P Anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249 ± nivolumab (NIVO) in patients (pts) with advanced cancers: Updated phase I results (2022) (0)
- Cyclophosphamide for Metastatic Cancer Combined with GM-CSF, Pegylated IFN, and Loaded with Autologous Tumor Lysates Pilot Clinical Trial of Type 1 Dendritic Cells (2011) (0)
- Abstract LB-196: Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects (2010) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ignacio Melero?
Ignacio Melero is affiliated with the following schools:
